{"entity":{"id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","aka":["KEVLARx"],"tldr":"A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by EpicentRx, Inc., active and no longer recruiting.","summary":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer is a phase 2 interventional study registered as NCT05966194 by EpicentRx, Inc., with 216 participants enrolled, started 2024-04-02 and due to reach its primary completion in 2027-07-01. Interventions recorded: RRx-001, Intensity Modulated Radiation Therapy (IMRT) and Cisplatin for injection 100 mg/m2.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05966194","url":"https://clinicaltrials.gov/study/NCT05966194"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck","oral-cavity-cancer","oropharyngeal-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cisplatin"],"companies":["epicentrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05966194","phase":"2","setting":"A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx","sponsor":"EpicentRx, Inc.","participation":[{"nct":"NCT05966194","source":"https://clinicaltrials.gov/study/NCT05966194","fetchedAt":"2026-10-07T16:54:03.729Z","studySha256":"78a5552916ee37def9ddbe6eb034209eacd906d793d9a71e2f5970a84d6425d6","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-26","leadSponsor":"EpicentRx, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":216,"enrolmentType":"ESTIMATED","siteCount":14,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2024-04-02","startedType":"actual","enrolled":216,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05966194/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"oral-cavity-cancer","kind":"cancer","name":"Oral cavity cancer (mouth and tongue)","route":"/cancers/oral-cavity-cancer/"},{"id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}],"company":[{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/"}]}}